Merit Medical Systems (MMSI) Expected to Post Quarterly Earnings on Thursday

Merit Medical Systems (NASDAQ:MMSI) is expected to announce its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to announce earnings of $1.04 per share and revenue of $410.34 million for the quarter. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

Merit Medical Systems (NASDAQ:MMSI) last announced its quarterly earnings data on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.23. Merit Medical Systems had a net margin of 9.22% and a return on equity of 13.75%. The business had revenue of $418.84 million during the quarter, compared to the consensus estimate of $405.25 million. During the same quarter last year, the firm earned $1.01 earnings per share. The firm’s quarterly revenue was up 9.5% compared to the same quarter last year. On average, analysts expect Merit Medical Systems to post $3.84 EPS for the current fiscal year and $4.17 EPS for the next fiscal year.

Merit Medical Systems Stock Up 1.0%

Shares of NASDAQ:MMSI opened at $94.20 on Tuesday. Merit Medical Systems has a 1 year low of $59.74 and a 1 year high of $94.85. The business has a 50 day simple moving average of $88.45 and a two-hundred day simple moving average of $77.08. The firm has a market capitalization of $5.62 billion, a PE ratio of 25.42, a price-to-earnings-growth ratio of 2.33 and a beta of 0.51. The company has a debt-to-equity ratio of 0.44, a current ratio of 4.20 and a quick ratio of 2.79.

Analyst Ratings Changes

Several brokerages have recently weighed in on MMSI. Raymond James Financial reiterated an “outperform” rating and issued a $100.00 price target on shares of Merit Medical Systems in a report on Friday, July 31st. Canaccord Genuity Group boosted their price objective on Merit Medical Systems from $85.00 to $94.00 and gave the company a “buy” rating in a report on Friday, July 31st. Needham & Company LLC reaffirmed a “buy” rating and issued a $101.00 price objective on shares of Merit Medical Systems in a research report on Tuesday, September 29th. Zacks Research downgraded Merit Medical Systems from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 19th. Finally, JPMorgan Chase & Co. increased their target price on Merit Medical Systems from $77.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Eight equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $100.00.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a medical device company that develops, manufactures and distributes disposable products used in interventional, diagnostic and therapeutic procedures. Its devices are designed for use by healthcare professionals in hospitals, outpatient facilities and other clinical settings.

The company’s product portfolio includes devices for vascular access, angiography, intervention, drainage, embolization, oncology and cardiac procedures. Merit also offers products used in peripheral intervention, spine procedures and other specialized areas of minimally invasive medicine, including kits, accessories and related procedural equipment.

Founded in 1987 and headquartered in South Jordan, Utah, Merit Medical serves healthcare providers through a global commercial and manufacturing network.